drugset / Trial / NCT01873885
Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension
RandomizedSingle-groupTriple-blindTreatment
Summary
This study is an exploratory Phase 1 randomized, double-blind (Investigator and study subject and 2-D echo endpoint assessor), placebo-controlled single IV infusion dose escalation study that will enroll up to approximately 32 subjects with stage 1 or 2 essential hypertension.
Timeline
- Start
- 2013-06
- Primary completion
- 2014-03
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemziviptadil | Peptide | 0.005 mg/kg | Intravenous |
| Subject | Pemziviptadil | Peptide | 0.01 mg/kg | Intravenous |
| Subject | Pemziviptadil | Peptide | 0.02 mg/kg | Intravenous |